Similar Virologic Outcomes and Frequency of Isolated Viremic Events (Blips, Low-Level Viremia and Suspected Virologic Failure) Between Oral and Long-acting Antiretroviral Therapy: A Pooled Analysis of Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies

P040

John Thornhill[1], Louise Garside[2], Chinyere Okoli[1], Patricia de los Rios[3], Kimberley Brown[4], Lori A. Gordon[4], Christine L. Latham[4], William Spreen[4]

[1]ViiV Healthcare, London, United Kingdom; [2]PHASTAR, Macclesfield, United Kingdom; [3]ViiV Healthcare, Laval, QC, Canada; [4]ViiV Healthcare, Durham, NC, United States

Please scan the QR code to access a copy of the poster and a plain language summary of the poster

Key Takeaways

- This *post hoc* analysis describes the low frequency of predefined viral events (viral blips, low-level viremia [LLV], and isolated suspected virologic failure [SVF]) and examines subsequent virologic outcomes through 1 year in cabotegravir + rilpivirine long-acting (CAB + RPV LA) Phase 3/3b studies.
- The proportion of participants with confirmed virologic failure (CVF) was low (<1%) and comparable between CAB + RPV LA and oral antiretroviral therapy (ART); viral blips and LLV were not associated with CVF.
- Isolated SVF events were rare, with similar rates of subsequent CVF with CAB + RPV LA and comparator oral ART.
- These data suggest similar CVF outcomes after isolated viremic events with both CAB + RPV LA and oral ART, supporting the noninferior efficacy of CAB + RPV LA vs. oral ART for the maintenance of virologic suppression in people with HIV-1 (PWH).

Introduction

- CAB + RPV LA administered intramuscularly is the first and only complete LA regimen recommended by treatment guidelines for virologically suppressed PWH.[1–3]
- The definition and management of viremia, viral rebound, and virologic failure varies across clinical studies and guidelines;[1,2,4,5] therefore, clearly defining the various types of viremic events occurring in clinical trials may help healthcare providers in their management of PWH.
- In Phase 3/3b clinical studies, low and comparable numbers of viral blips were experienced by participants receiving CAB + RPV LA or daily oral ART; viral blips were not associated with virologic failure.[6–8]
- In this expanded analysis, we present virologic outcomes following predefined viral rebounds ≥50 copies/mL (viral blips or LLV) and ≥200 copies/mL (SVF) through 1 year in CAB + RPV LA Phase 3/3b studies.

Methods

- FLAIR (NCT02938520), ATLAS (NCT02951052), ATLAS-2M (NCT03299049), and SOLAR (NCT04542070) were Phase 3/3b, randomized, open-label, multicenter studies assessing the efficacy and safety of CAB + RPV LA.
- Participants were virologically suppressed (HIV-1 RNA <50 copies/mL) at randomization.
- Viral load assessments were done at the following visits:
  - FLAIR and ATLAS: screening, Day 1, and every month thereafter (Week [W] 4, W8, W12, W16, W20, W24, W28, W32, W36, W40, W44, and W48).
  - ATLAS-2M: screening, Day 1, and every two months thereafter (W4 [oral lead-in only], W8, W16, W24, W32, W40, and W48).
  - SOLAR: screening, Day 1, and every two months thereafter (Month [M] 2, M4, M6, M8, and M12 for oral lead-in and oral ART participants; M1, M3, M5, M7, M9, and M11 for participants starting with injection).
- In this pooled *post hoc* analysis, we describe the frequency of predefined viral events (**Table 1**) through Week 48 in FLAIR, ATLAS, and ATLAS-2M, and through Month 12 in SOLAR.

Table 1. Predefined Viral Events Assessed *Post Hoc*

Viral event	Definition
Viral blips	A single viral load between 50 and <200 copies/mL, with adjacent values <50 copies/mL.
LLV	≥2 consecutive viral loads between 50 and <200 copies/mL.
Isolated SVF	A single plasma viral load ≥200 copies/mL, with the subsequent value <200 copies/mL. Further divided into:* • A single viral load ≥200–<500 copies/mL • A single viral load ≥500–<1000 copies/mL • A single viral load ≥1000 copies/mL
CVF	Two consecutive HIV-1 RNA values ≥200 copies/mL.

*All with the subsequent adjacent viral load <200 copies/mL.

Results

- Overall, 2506 participants were included in the analysis (CAB + RPV LA, n=1692; comparator oral ART, n=814).
- Baseline characteristics were similar between treatment groups (**Table 2**).
- Overall, CVF occurred in <1% of participants (CAB + RPV LA, n=16/1692; oral ART; n=7/814).

Table 2. Baseline Characteristics

Parameter	CAB + RPV LA (n=1692)	Oral ART (n=814)*
Age, median (range), years	39 (18–83)	38 (18–82)
≥50 years, n (%)	360 (21)	167 (21)
Sex at birth, n (%)		
Female	387 (23)	209 (26)
Male	1305 (77)	605 (74)
Gender identity,† n (%)		
Female	392 (23)	209 (26)
Male	1288 (76)	601 (74)
Transgender female	9 (<1)	3 (<1)
Transgender male	1 (<1)	0
Gender variant or gender non-conforming	1 (<1)	0
Other gender identities	1 (<1)	1 (<1)
Race, n (%)		
White	1232 (73)	566 (70)
Black/African American	306 (18)	181 (22)
Asian	86 (5)	40 (5)
Other races	68 (4)	27 (3)
Ethnicity, n (%)		
Hispanic or Latinx	250 (15)	112 (14)
Median BMI, kg/m^2 (range)	25.4 (15–65)	25.0 (16–68)
≥30 kg/m^2, n (%)	306 (18)	155 (19)

*Oral regimens were: DTG/ABC/3TC (n=283; FLAIR [participants with side effects to this therapy, or who were positive for HLAB*5701, received DTG + 2 non-ABC NRTIs]), BIC/FTC/TAF (n=223; SOLAR), and various standard oral therapies (n=308; ATLAS). †Self-reported gender. ART, antiretroviral therapy; BIC/FTC/TAF, bictegravir/emtricitabine/tenofovir alafenamide; BMI, body mass index; CAB, cabotegravir; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; LA, long-acting; NRTI, nucleoside reverse transcriptase inhibitor; RPV, rilpivirine.

- Overall, 6% (n=97/1692) and 7% (n=61/814) of participants experienced viral blips with CAB + RPV LA and oral ART, respectively (**Table 3**).
- The proportion of participants with LLV was similar between treatment arms (CAB + RPV LA, 1% [n=18/1692]; oral ART, 1% [n=10/814]).
- There were few isolated SVF events (**Figure 1**), occurring in ≤2% of participants in both arms (**Table 3**).

Figure 1. Isolated SVF Population (CAB + RPV LA and Oral ART)



The dashed box shows analysis of isolated SVF data for CAB + RPV LA (n=12/1692) and oral ART (n=13/814) combined.
*Viral loads ranged from 202 copies/mL to 737,830 copies/mL. †Within 1 year from the start of maintenance treatment.
ART, antiretroviral therapy; CAB, cabotegravir; CVF, confirmed virologic failure; LA, long-acting; RPV, rilpivirine; SVF, suspected virologic failure.

Table 3. Proportion of Participants With Blips, LLV, and Isolated SVF Through 1 Year*

n (%)	CAB + RPV LA (n=1692)	Oral ART (n=814)
Blips	97/1692 (6)	61/814 (7)
LLV†	18/1692 (1)	10/814 (1)
Isolated SVF‡	12/1692 (<1)	13/814 (2)
Isolated SVF 200–<500 copies/mL	9/1692 (<1)	4/814 (<1)
Isolated SVF 500–<1000 copies/mL	3/1692 (<1)	5/814 (<1)
Isolated SVF >1000 copies/mL	0/1692	4/814 (<1)

*Participants with vaccination within a month prior – Blips: CAB + RPV LA, n=11; oral ART, n=8; LLV: CAB + RPV LA, n=2; oral ART, n=1. †≥2 consecutive viral loads 50–<200 copies/mL. ‡A single plasma HIV-1 RNA value ≥200 copies/mL, with the subsequent value <200 copies/mL. ART, antiretroviral therapy; CAB, cabotegravir; LA, long-acting; LLV, low-level viremia; RPV, rilpivirine; SVF, suspected virologic failure.

- The proportions of participants with viral blips were consistently ≤2% across both arms at all timepoints.
- The proportions of participants with LLV at each visit were consistently <1% across the treatment arms (**Figure 2**).
- The proportions of participants with isolated SVF at each visit were also consistently <1% across the treatment arms (**Figure 3**).

Figure 2. Proportion of Participants With LLV by Visit



ART, antiretroviral therapy; CAB, cabotegravir; LA, long-acting; LLV, low-level viremia; RPV, rilpivirine; W, week.

Figure 3. Proportion of Participants With Isolated SVF by Visit



ART, antiretroviral therapy; CAB, cabotegravir; LA, long-acting; RPV, rilpivirine; SVF, suspected virologic failure; W, week.

- The number of participants with previous viral blips or LLV experiencing CVF was low across both arms (**Figure 4**).

Figure 4. Participants Experiencing CVF With Previous Blips and LLV



ART, antiretroviral therapy; CAB, cabotegravir; CVF, confirmed virologic failure; LA, long-acting; LLV, low-level viremia; RPV, rilpivirine.

- Overall, three of 12 participants in the CAB + RPV LA arm with an isolated SVF event had subsequent CVF compared with three of 13 participants in the oral ART arm.
- Participants with CVF according to previous isolated SVF viral load were:
  - A single viral load 200–<500 copies/mL: CAB + RPV LA, n=2/9; oral ART, n=1/4.
  - A single viral load 500–<1000 copies/mL: CAB + RPV LA, n=1/3; oral ART, n=1/5.
  - A single viral load ≥1000 copies/mL: CAB + RPV LA, n=0; Oral ART, n=1/4.

Conclusions

- In this expanded pooled analysis across four Phase 3/3b studies, CVF rates were low (<1%) and similar between CAB + RPV LA and oral ART through 1 year.
- The frequency of viral blips was similar with both CAB + RPV LA and oral ART, and viral blips were not associated with CVF, consistent with prior analyses.[6–8]
- The proportion of participants with LLV was low (<1%) at all time points across both arms and was not associated with CVF.
- There were few isolated SVF events, with similar rates of subsequent CVF occurring with CAB + RPV LA and comparator oral ART.
- These data suggest similar outcomes after isolated viremic events with both regimens, supporting the noninferior efficacy of CAB + RPV LA vs. oral ART for the maintenance of virologic suppression in PWH.

Acknowledgments: We thank everyone who has contributed to the success of the FLAIR, ATLAS, ATLAS-2M, and SOLAR studies; all study participants and their families, and the clinical investigators and their staff. The analysis is funded by ViiV Healthcare. Editorial assistance was provided by Poppy Mashilo of Nucleus Global, with funding provided by ViiV Healthcare.

References: 1. U.S Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed October 2024. **2.** European AIDS Clinical Society. Guidelines Version 11.1. 2022. Available from: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf. Accessed October 2024. **3.** Gandhi RT, et al. *JAMA*. 2023;329(1):63–84. **4.** Saag MS, et al. *JAMA*. 2020;324(16):1651–1669. **5.** Hanners EK, et al. *Drugs Context*. 2022;11:2021–8–23. **6.** Latham C, et al. HIV Drug Therapy Glasgow 2022 (Poster P083). **7.** Talarico C, et al. IDWeek 2020 (Poster 1021). **8.** Latham C, et al. CROI 2024 (Poster 627).

Presenting author: John Thornhill; john.p.thornhill@viivhealthcare.com